Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions

XOMA (XOMA) Uses License Deals and Restructuring to Extend Runway to 2017; Piper Jaffray Remains Neutral

November 6, 2015 10:35 AM EST

Piper Jaffray reiterated a Neutral rating on XOMA, Ltd. (NASDAQ: XOMA), and raised the price target to $1.80 (from $1.50), following the company's 3Q earnings report. XOMA ended 3Q:15 with $32 million. The company subsequently received $37 million from Novartis for TGF-beta upfront and $5 million from Agenus for an... More